TG Therapeutics ((TGTX)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: TG Therapeutics is conducting a study titled ‘REal World ExperieNce With BRIUMVI® (UblituximAB-xiiy) Treated Patients: A Longitudinal REgistry Study (ENABLE)’ to assess the safety, effectiveness, and treatment experience of BRIUMVI® (ublituximab-xiiy) in patients with Relapsing Multiple Sclerosis (RMS). This study is significant as it aims to provide real-world insights into the drug’s performance outside of controlled clinical trials.
Intervention/Treatment: The intervention being tested is BRIUMVI® (ublituximab-xiiy), administered through intravenous infusion. It is designed to treat patients with Relapsing Multiple Sclerosis by potentially reducing the frequency of relapse episodes.
Study Design: This is an observational study with a case-only model and a prospective time perspective. The primary purpose is to gather data on the real-world application of BRIUMVI® without any specific allocation or masking involved.
Study Timeline: The study began on May 23, 2024, with the latest update submitted on September 30, 2025. These dates are crucial as they mark the study’s progress and ongoing data collection, which investors should monitor for future updates.
Market Implications: The ongoing study could influence TG Therapeutics’ stock performance positively if BRIUMVI® demonstrates favorable real-world outcomes. This could enhance investor sentiment and position the company competitively within the multiple sclerosis treatment market, especially against other pharmaceutical companies targeting similar conditions.
The study is currently recruiting, with further details available on the ClinicalTrials portal.